TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02781818
Drug: Triamcinolone Acetonide 40mg/mL
Normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
Study: NCT03166501
Drug: Lanicemine
Normalized name: Lanicemine
DrugBank: Lanicemine (DB11889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 60 min parenteral infusions over a 5 day period
Study: NCT01594918
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 or 20 mg/m2, IV, once every 21 days
Study: NCT01594918
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
Study: NCT01594918
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg PO BID
Study: NCT01594918
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg, SC, once every 21 days
Study: NCT02366299
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment of delirium by dexmedetomidine i.v. infusion
Study: NCT02366299
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of delirium by Propofol i.v. infusion
Study: NCT01030016
Drug: atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/day, twice a day for 6 weeks
Study: NCT01703169
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
Study: NCT01569945
Drug: Menotropins
Normalized name: menotropins
DrugBank: Menotropins (DB00032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
Study: NCT02726789
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immunotherapy
Study: NCT02726789
Drug: entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local generic entecavir
Study: NCT01589419
Drug: veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm description
Study: NCT02554045
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
Study: NCT01307891
Drug: Abraxane alone
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
Study: NCT01307891
Drug: Abraxane + Tigatuzumab
Normalized name: Abraxane
DrugBank: Tigatuzumab (DB15101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
Study: NCT04331834
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months
Study: NCT01751321
Drug: Sitagliptin, placebo
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
Study: NCT01754324
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
Study: NCT02867332
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
Study: NCT00191984
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
Study: NCT00191984
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
Study: NCT02771457
Drug: Infliximab at weeks 0,2, and 6
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02771457
Drug: Infliximab at weeks 0,4, and 8
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00197431
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03303521
Drug: Sodium Zirconium Cyclosilicate (ZS)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
Study: NCT01725087
Drug: Low Dose GRT6005
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01725087
Drug: High Dose GRT6005
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01725087
Drug: Tapentadol
Normalized name: Tapentadol
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02771457
Drug: Infliximab at weeks 0 and 8
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
Study: NCT00002917
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00669149
Drug: clopidogrel + aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00669149
Drug: heparin + clopidogrel + aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00669149
Drug: enoxaparin + clopidogrel + aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02033707
Drug: Hallucinogens and psychoactive substances
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.
Study: NCT00669149
Drug: bivalirudin + clopidogrel + aspirin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03905837
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous or paravertebral lidocaine
Study: NCT03941990
Drug: Fixed 50:50 mixture of nitrous oxide and oxygen
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
Study: NCT01520207
Drug: Mannitol (20%)
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
Study: NCT00423280
Drug: 6R-BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Study: NCT04203212
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
Study: NCT03837457
Drug: Cobomarsen
Normalized name: Cobomarsen
DrugBank: Cobomarsen (DB14931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
Study: NCT03642535
Drug: ALA
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
Study: NCT00112918
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
Study: NCT00112918
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an intravenous infusion over 2 hours.
Study: NCT02964338
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
Study: NCT01653457
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~* 1st week: 5 mg daily~* 2nd week: 10 mg daily~* 3rd week: 15 mg daily~* From 4th week up to 24th week: 20 mg daily
Study: NCT01737411
Drug: solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03258645
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (NOAC) thrombin inhibitor
Study: NCT01308034
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring.
Study: NCT02171429
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
Study: NCT02171429
Drug: Etrolizumab
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study: NCT03952572
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4mg/m²(Maximum 2 mg) ivgtt on day 1
Study: NCT03952572
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone100mg/m² po on day1-5
Study: NCT04572776
Drug: Resiniferatoxin
Normalized name: resiniferatoxin
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.
Study: NCT01156688
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
Study: NCT01156688
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
Study: NCT00452660
Drug: Exjade
Normalized name: Exjade
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04037514
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous paracetamol 15 mg/kg/6h
Study: NCT02299388
Drug: Liraglutide or Placebo
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
Study: NCT00570336
Drug: CTS-1027
Normalized name: CTS-1027
DrugBank: CTS-1027 (DB08490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
Study: NCT00701688
Drug: Palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
Study: NCT03620149
Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Normalized name: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 120 mg, SC, on day 1 of every 12-week cycle
Study: NCT02548052
Drug: Betamethasone valerate 0.1%
Normalized name: BETAMETHASONE VALERATE 0.1% OINT
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
Study: NCT02754518
Drug: Entresto
Normalized name: Entresto
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06086665
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib
Study: NCT04057937
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast
Study: NCT04190862
Drug: E-CEL UVEC
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of E-CEL UVEC
Study: NCT03363867
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
Study: NCT03363867
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
Study: NCT03363867
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
Study: NCT03868839
Drug: Telmisartan Pill
Normalized name: telmisartan Pill
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
Study: NCT00401128
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00401128
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00027885
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
Study: NCT01787669
Drug: Avastin (Bevacizumab)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin (Bevacizumab) administered intravitreally
Study: NCT01787669
Drug: Ozurdex (dexamethasone)
Normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ozurdex (dexamethasone) given intravitreally
Study: NCT02768168
Drug: dezocine
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive dezocine 0.1 mg/kg
Study: NCT01753713
Drug: dovitinib
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04349124
Drug: Nifedipine Extended-Release Tablets
Normalized name: Nifedipine Extended-Release Tablets
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antihypertensive
Study: NCT01007851
Drug: triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
Study: NCT03210493
Drug: Peginterferon Alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
Study: NCT00171990
Drug: Famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00317746
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05983328
Drug: HUYPS-1 one tablet
Normalized name: 1-dodecylazacycloheptan-2-one
DrugBank: Laurocapram (DB17308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
Study: NCT01651416
Drug: Dihydroartemisinin Piperaquine combination
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01896193
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01837251
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00705757
Drug: latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
Study: NCT00705757
Drug: bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
Study: NCT01651416
Drug: Amodiaquine plus sulphadoxine-pyrimethamine combination
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00705757
Drug: travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
Study: NCT02028507
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02028507
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02028507
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00005032
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01750060
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01543802
Drug: pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
Study: NCT02493452
Drug: Plecanatide
Normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00527826
Drug: Salmeterol / Fluticasone (50/500 µg) BID fixed combination
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: comparator
Study: NCT00837967
Drug: Terbutaline Turbuhaler
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mg for 3 days
Study: NCT02585713
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO